CORDIS
EU research results

CORDIS

English EN

The hiv-1 pathogenicity factor nef as a novel therapeutic target

Project information

Grant agreement ID: QLK2-CT-2000-01630

  • Start date

    1 September 2000

  • End date

    30 November 2003

Funded under:

FP5-LIFE QUALITY

  • Overall budget:

    € 1 300 000

  • EU contribution

    € 1 300 000

Coordinated by:

UNIVERSITY OF TAMPERE

Finland

Objective

Neff is a lent viral protein critical for AIDS pathogenesis. In addition to increasing HIV replication, Net has an independent role as a major pathogenicityfactor, as revealed by recent work in transgenic mice. This two-fold contribution of Neff to the pathogenesis of AIDS suggests that compounds that could block Neff unction would be potent anti-AIDS drugs. Despite this remarkable promise, Neff has so far not been exploited as a therapeutic target. The objective of the proposed collaborative project is to extend the ongoing basic research in the individual laboratories of this consortium towards the common and more applied goal of transforming Neff into a therapeutic target that would be attractive and readily available to the pharmaceutical industry for exploitation in drug discovery, goal that conforms well to objectives of the thematic priority 1.1.1. -2.2.1 of thee Fifth Framework Programme.

Coordinator

UNIVERSITY OF TAMPERE

Address

6,LenkkeilijÄNkatu 6
33014 Tampere

Finland

Participants (4)

INSTITUT PASTEUR

France

UNIVERSITAETSKLINIKUM HEIDELBERG

Germany

UNIVERSITY OF ERLANGEN-NUREMBERG

Germany

UNIVERSITY OF LEEDS

United Kingdom

Project information

Grant agreement ID: QLK2-CT-2000-01630

  • Start date

    1 September 2000

  • End date

    30 November 2003

Funded under:

FP5-LIFE QUALITY

  • Overall budget:

    € 1 300 000

  • EU contribution

    € 1 300 000

Coordinated by:

UNIVERSITY OF TAMPERE

Finland